Acambis Expands Manufacturing Capability

Acambis announces that it has acquired a U.S.-based fill/finish facility from BioReliance, a wholly owned subsidiary of Invitrogen. With the acquisition, Acambis intends to develop a commercial-scale fill/finish capability suitable for many of the vaccines in its development pipeline, which includes the ACAM2000 and MVA3000 smallpox vaccines, ChimeriVax-JE, ChimeriVax-West Nile and C. difficile. This acquisition fits with Acambis' strategy of creating a complete internal supply chain with the objective of enabling it to take a vaccine from development to market.

PharmaLive (http://www.medadnews.com/News/Index.cfm?articleid=237971)